Mysimba: Consider for your patients with emotional eating. Mysimba helps control hunger & cravings due to its mode of action in the brain 1,2 † *
Guidelines suggest the use of Mysimba 1st line for patients with obesity and cravings.2
It has proven efficacy in weight loss. Patients in the responders group lost an average of 11.7% of their baseline weight at 1 year.3#
You and your patient will know at 16 weeks if MYSIMBA works. 1
Mysimba is an oral tablet suitable for patients who prefer a non-injectable medicine.1
#versus 8.8% weight loss among patients receiving placebo. Responders lost ≥5% of their baseline body weight by week 16.
*The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood
Mysimba (8mg / 90mg Naltrexone / Bupropion) is a prescription only medicine. Mysimba is an oral treatment licensed as an adjunct to a reduced-calorie diet and increased physical activity for the management of weight in adults with:1
- an initial BMI of ≥30 kg/m² (obesity), or
- ≥27 kg/m² (overweight) in the presence of comorbidities such as type 2 diabetes or controlled hypertension.
Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.
Conquer Cravings where it counts
Mysimba helps to control hunger and cravings due to its mode of action in the brain.*
Mysimba contains naltrexone and bupropion which work together on the 2 areas of the brain responsible for hunger, the hypothalamus, and the body’s natural reward system, the mesolimbic system.1
*The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood
Guidelines suggest the use of Mysimba 1st line for patients with Obesity and Cravings
The Association for the study of Obesity on the Island of Ireland (ASOI) have developed Clinical Practice Guidelines for the Management of Obesity in Irish adults.
The ASOI Guidelines suggest the use of Mysimba 1st line for patients with obesity and cravings.2
Mysimba has proven efficacy in weight loss
Mysimba was compared to placebo in 3 clinical trials over 56 weeks. All participants were instructed to diet and exercise. In the studies, people taking Mysimba lost 2-4x more weight compared to those who used diet and exercise alone. 4,5,6
In a real-world setting after 6 months of Mysimba treatment with adjunctive lifestyle modification participants experienced decreased appetite (14.7%), decreased cravings (13.9%), decreased hunger (9.4%) and felt full sooner (2.5%).7
Mysimba is an oral tablet suitable for patients who prefer a non-injectable medicine 1
Mysimba supports long-term weight management in patients with obesity.
Mysimba Leave Piece
Patient Profile
Mysimba MOA
Mysimba Patient Leaflet
Mysimba Physician Prescribing Checklist
- Mysimba 8 mg/90 mg prolonged-release tablets Summary of Product Characteristics available on medicines.ie or www.ema.europa.eu
- Le Roux et al, Algorithm: Choice of Obesity Pharmacotherapy, Chapter: Pharmacotherapy in Obesity Management, ASOI Clinical Practice Guideline for the Management of Obesity in Adults in Ireland, p15.
- Fujioka, Plodkowski R, O’Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss as 1 year with Naltrexone ER / Bupropion ER combination therapy. Int J Obesity (Lond.) 2016; 40: 1369-1375.
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
- Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011(1);19:110-120.
- Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
- Wharton et. al, The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review, Clin Obes. 2025 Apr;15(2):e12724. doi: 10.1111/cob.12724. Epub 2024 Dec 1.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
*The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood
IE-MYS-208(1), MYS-0454-001 01/26 DOP:January 2026
The information on this website is intended for Healthcare Professionals who reside in Ireland and Malta only.
Healthcare professionals who reside in Ireland are asked to report any suspected adverse events to: HPRA Pharmacovigilance via www.hpra.ie;
Adverse events should also be reported to Orexigen: +353 1800 849 099 or Currax.Ml@primevigilance.com.
Healthcare professionals who reside in Malta are asked to report any suspected adverse events to: the Malta Medicines Authority via http://medicinesauthority.gov.mt/adrportal or Vivian Corporation Ltd. via pv@viviancorp.com.
Adverse events should also be reported to Orexigen: +356 800 62176 or Currax.Ml@primevigilance.com.